We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Concurrent DNA and RNA Sequencing Improves Accuracy of Hereditary Cancer Testing

By LabMedica International staff writers
Posted on 06 Nov 2023
Print article
Image: Expanding clinical use of RNA sequencing improves diagnostic yield and reduces inconclusive rates (Photo courtesy of Ambry Genetics)
Image: Expanding clinical use of RNA sequencing improves diagnostic yield and reduces inconclusive rates (Photo courtesy of Ambry Genetics)

A new study has shown that combining RNA sequencing with DNA sequencing is a significant step forward in genetic testing, particularly for identifying genetic predispositions to cancer. This dual approach enhances the discovery of new gene variants and refines our understanding of known variants, leading to better identification of individuals at risk for hereditary cancers and more tailored options for treatment and monitoring.

Scientists at Ambry Genetics (Aliso Viejo, CA, USA) explored the impact of pairing DNA and RNA testing on detecting disease-causing germline genetic variants and resolution of variants of uncertain significance (VUS). Their study included 43,524 people who were tested for hereditary cancer risk. They found that using RNA sequencing alongside DNA testing not only improved the rate at which they identified disease-related genetic variants but also reduced the number of inconclusive findings. Specifically, RNA sequencing influenced the classification of 17.1% of splicing variants deemed pathogenic, which is about 1.9% of all variants identified as pathogenic. It also helped to reclassify 71.1% of splicing variants previously labeled as uncertain — equating to 2.1% of all variants of uncertain significance — as benign.

These results are transformative in the field of genetic testing for cancer risk, with a shift towards a more integrated multiomic approach. The advantage of this method is that it gives patients and healthcare providers a more comprehensive and definitive genetic profile for making informed and timely medical decisions. As genetic testing evolves, the integration of RNA sequencing is becoming increasingly important in the pursuit of personalized medicine, significantly improving the ability to detect and categorize genetic variations linked to hereditary cancer.

"The integration of DNA with RNA sequencing into germline cancer predisposition evaluation is the new gold standard for genetic testing,” said Rachid Karam, M.D., Ph.D., VP of Research & Development at Ambry Genetics and lead investigator of the study. “We’ve witnessed a remarkable improvement in diagnostic accuracy and a substantial reduction in inconclusive results. Patients benefit from having access to the most comprehensive genetic testing possible, as demonstrated by the thousands of individuals impacted by RNA testing in our laboratory cohort alone.”

Related Links:
Ambry Genetics

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TETANUS Test
TETANUS VIRCLIA IgG MONOTEST
New
Auto Clinical Chemistry Analyzer
cobas c 703

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.